GO:0101005 deubiquitinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0101005 deubiquitinase activity is an isopeptidase activity that removes ubiquitin from conjugated target proteins, reversing ubiquitination and controlling protein stability, localization and signaling.
• Deubiquitinases (DUBs) are highly specific and tightly regulated enzymes; their catalytic domains and accessory domains determine substrate selection and cellular context.
• DUBs control diverse processes including proteostasis, DNA repair, immune signaling, ferroptosis and metabolism, and are implicated in cancer and metabolic disease [2,3,5,6].
• The proteasome-associated DUB PSMD14/RPN11 has histone deubiquitinase activity and drives myelomagenesis, linking DUB activity directly to chromatin regulation and cancer.
• Inhibiting RPN11 ameliorates nonalcoholic fatty liver disease, showing that DUBs are actionable therapeutic targets in metabolic disorders.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of DUB function and are supported by proteome-scale effector discovery platforms.
Description
Deubiquitinase activity (GO:0101005) is a molecular function defined as an isopeptidase activity that cleaves ubiquitin from a target protein to which it is conjugated. This activity reverses ubiquitination, a post-translational modification that controls protein degradation, trafficking, interaction and signaling. Because ubiquitination is reversible, DUBs act as critical rheostats that determine the fate of thousands of proteins and shape nearly every cellular pathway. Researchers study GO:0101005 to understand how cells maintain proteostasis, respond to stress and regulate immune and metabolic signaling. The importance of this activity is underscored by the large number of human DUBs and their links to cancer, inflammation, ferroptosis and metabolic disease [2,3,5,6]. For example, the proteasome component PSMD14 (RPN11) exhibits histone deubiquitinase activity that drives myelomagenesis, directly connecting DUB catalysis to epigenetic regulation and tumorigenesis. Similarly, inhibition of RPN11 ameliorates nonalcoholic fatty liver disease, demonstrating that DUB activity can be targeted therapeutically in metabolic disorders. As a result, GO:0101005 is a central node for functional genomics, drug discovery and mechanistic cell biology.
deubiquitinase activity At A Glance
| GO ID | GO:0101005 |
|---|---|
| GO term | deubiquitinase activity |
| Ontology | molecular_function |
| Synonym | ubiquitinyl hydrolase activity |
| Definition | An isopeptidase activity that cleaves ubiquitin from a target protein to which it is conjugated. |
| Major function | Reverses ubiquitination by removing ubiquitin from substrate proteins, thereby regulating protein stability, localization and signaling. |
| Enzyme class | Isopeptidase / cysteine protease or metalloprotease, depending on the DUB family. |
| Substrates | Ubiquitin-conjugated proteins, including histones, signaling adaptors and metabolic enzymes [1,2]. |
| Representative genes | PSMD14, OTUD5, OTUD3, OTUD1 and many other DUB-encoding genes [1,3,4,5,8]. |
What Is GO:0101005?
In simple terms, deubiquitinase activity is the enzymatic ability to cut ubiquitin off a protein. According to the QuickGO definition, it is an isopeptidase activity that cleaves ubiquitin from a target protein to which it is conjugated. This activity is also known as ubiquitinyl hydrolase activity. It belongs to the molecular_function ontology and is mediated by enzymes called deubiquitinases (DUBs), which recognize ubiquitinated substrates and hydrolyze the isopeptide bond between ubiquitin and the target protein. By removing ubiquitin, DUBs can rescue proteins from degradation, alter their localization or activity, and recycle ubiquitin moieties. The reaction is highly specific and regulated, often through multidomain architectures that combine catalytic domains with ubiquitin-binding modules.
Why Is deubiquitinase activity Important in Cell Biology?
Deubiquitinase activity is essential because it provides the reversibility that makes ubiquitin signaling dynamic and tunable. Without DUBs, cells could not recycle ubiquitin, correct aberrant ubiquitination or rapidly adjust protein levels in response to stress. DUBs control fundamental processes such as proteasomal degradation, DNA damage repair, NF-kB signaling, ferroptosis and metabolic homeostasis [2,3,5,8]. Their dysfunction is linked to cancer, inflammatory diseases and metabolic disorders, making them high-value targets for basic and translational research [1,4,6].
• DUBs reverse ubiquitination and thus control protein half-life, localization and activity.
• They regulate proteasome function; PSMD14/RPN11 is a proteasome-associated DUB with histone deubiquitinase activity.
• DUBs modulate immune signaling; OTUD1 suppresses RIPK1-mediated NF-kB signaling and colonic inflammation.
• OTUD5 protects against 4-HNE-triggered ferroptosis in myocardial ischemia/reperfusion injury.
• OTUD3 regulates metabolic homeostasis in response to nutritional stresses.
• Inhibition of RPN11 ameliorates nonalcoholic fatty liver disease, highlighting therapeutic potential.
• DUBs are frequently dysregulated in cancer and represent candidate drug targets.
• Proteome-scale effector discovery has identified DUBs as protein degradation and stabilization effectors.
• DUB specificity and regulation are governed by multidomain architectures and post-translational modifications.
• CRISPR-based models allow causal testing of DUB genes in disease-relevant contexts.
What Happens During deubiquitinase activity?
Substrate recognition and binding
In simple terms: The DUB first grabs onto a ubiquitinated protein.
Deubiquitinases recognize their substrates through a combination of catalytic domains and accessory ubiquitin-binding domains. These interactions provide specificity, ensuring that only particular ubiquitin linkages or particular target proteins are cleaved. Substrate recognition can be regulated by post-translational modifications and by binding partners, allowing DUBs to respond to cellular signals.
Catalytic cleavage of the isopeptide bond
In simple terms: The enzyme cuts the bond that attaches ubiquitin to the target protein.
Once bound, the DUB catalyzes hydrolysis of the isopeptide bond between the C-terminal glycine of ubiquitin and a lysine residue on the substrate. This reaction removes ubiquitin and reverses the modification. Different DUB families use cysteine protease or metalloprotease mechanisms, but the outcome is the same: release of free ubiquitin and an unmodified target protein.
Release and recycling of ubiquitin
In simple terms: The freed ubiquitin can be used again.
After cleavage, ubiquitin is released and can be re-conjugated to new substrates, maintaining the cellular pool of free ubiquitin. This recycling is critical during periods of high ubiquitination demand, such as proteotoxic stress.
Downstream consequences for the substrate
In simple terms: Removing ubiquitin changes what happens to the protein.
Deubiquitination can rescue a protein from proteasomal degradation, alter its subcellular localization, or change its interaction partners. For example, PSMD14/RPN11 removes ubiquitin from histones to influence gene expression and drive myelomagenesis. In metabolic contexts, DUB activity can stabilize or destabilize enzymes that control lipid homeostasis [4,5].
Key Genes Involved in GO:0101005 deubiquitinase activity
The following genes encode deubiquitinases or DUB-associated proteins that directly mediate or regulate GO:0101005 activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PSMD14 | Proteasome-associated DUB (RPN11) with histone deubiquitinase activity | Drives myelomagenesis; target in multiple myeloma |
| OTUD5 | OTU-domain DUB protecting against ferroptosis | Myocardial ischemia/reperfusion injury |
| OTUD3 | OTU-domain DUB regulating metabolic homeostasis | Nonalcoholic fatty liver disease and nutritional stress |
| OTUD1 | OTU-domain DUB suppressing RIPK1-mediated NF-kB signaling | Colonic inflammation and inflammatory bowel disease |
| RPN11 | Proteasome lid DUB (same as PSMD14) | Nonalcoholic fatty liver disease; inhibitor studies |
| USP7 | Ubiquitin-specific protease regulating p53 and DNA repair | Cancer and genome stability |
| USP28 | Ubiquitin-specific protease stabilizing oncoproteins | Cancer |
| BAP1 | BRCA1-associated DUB with tumor suppressor function | Cancer and chromatin regulation |
| CYLD | DUB regulating NF-kB and immune signaling | Inflammation and cancer |
| A20/TNFAIP3 | DUB and ubiquitin-binding protein controlling NF-kB | Autoimmunity and lymphoma |
| UCHL1 | Ubiquitin C-terminal hydrolase | Neurodegeneration and cancer |
| UCHL5 | Proteasome-associated DUB | Cancer and proteostasis |
| USP14 | Proteasome-associated DUB | Cancer and neurodegeneration |
| OTULIN | Linear ubiquitin-specific DUB | Inflammation and immune signaling |
| MYSM1 | Histone H2A DUB | Hematopoiesis and gene expression |
| BRCC3 | DUB in the BRCA1-A complex | DNA repair and cancer |
| COPS5 | COP9 signalosome subunit with DUB-like activity | Cell cycle and development |
| EIF3H | Translation initiation factor with DUB activity | Cancer and translation control |
How Is deubiquitinase activity Regulated?
Deubiquitinase activity is regulated at multiple levels. DUBs often contain accessory domains that autoinhibit the catalytic site until a substrate or binding partner relieves inhibition. Post-translational modifications such as phosphorylation and ubiquitination can alter DUB activity, localization and substrate selection. In addition, DUBs can be regulated by interacting proteins; for example, proteasome-associated DUBs are activated within the proteasome holoenzyme [1,4]. Metabolic cues also influence DUB function, as OTUD3 responds to nutritional stress to maintain metabolic homeostasis. Together, these layers ensure that GO:0101005 activity is context-dependent and precisely controlled.
deubiquitinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PSMD14 | Multiple myeloma / myelomagenesis | Knockout and point-mutation models in myeloma cell lines |
| OTUD5 | Myocardial ischemia/reperfusion injury and ferroptosis | Cardiomyocyte knockout and overexpression models |
| OTUD3 | Nonalcoholic fatty liver disease and metabolic stress | Liver-specific knockout and knock-in models |
| OTUD1 | Colonic inflammation and NF-kB signaling | Intestinal epithelial knockout and overexpression models |
| RPN11 | Nonalcoholic fatty liver disease | Pharmacological inhibition and knockout models |
Cancer
DUBs are frequently dysregulated in cancer, where they can stabilize oncoproteins or destabilize tumor suppressors. PSMD14/RPN11 drives myelomagenesis through histone deubiquitinase activity, linking DUB catalysis to epigenetic reprogramming in multiple myeloma. Many other DUBs, including USP7, USP28, BAP1 and CYLD, are implicated in tumorigenesis and are being explored as drug targets.
Metabolic and cardiovascular disease
DUB activity controls metabolic homeostasis and cell survival under stress. Inhibition of RPN11 ameliorates nonalcoholic fatty liver disease, demonstrating a causal role in lipid metabolism. OTUD3 regulates metabolic homeostasis in response to nutritional stresses. OTUD5 protects against 4-HNE-triggered ferroptosis in myocardial ischemia/reperfusion injury, highlighting DUBs as modulators of oxidative stress responses.
Inflammation and immune disorders
DUBs are central regulators of NF-kB signaling. OTUD1 inhibits colonic inflammation by suppressing RIPK1-mediated NF-kB signaling, suggesting that DUB activity can restrain inflammatory responses. Other DUBs such as A20/TNFAIP3 and CYLD are well-known negative regulators of NF-kB and are linked to autoimmunity and lymphoma.
From deubiquitinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is the DUB required for tumor growth? | CRISPR knockout in cancer cell lines and xenografts [1,6] |
| Does a specific catalytic residue mediate DUB activity? | Point-mutation knock-in of catalytic cysteine to alanine |
| Does a disease-associated variant alter DUB function? | Knock-in of the patient variant and functional assays |
| Where and when is the DUB expressed? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of the DUB phenocopy disease? | Doxycycline-inducible overexpression models |
| Which substrates are stabilized upon DUB loss? | Knockout followed by proteomics and ubiquitin remnant profiling |
How to Study the deubiquitinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ubiquitin remnant profiling | Changes in ubiquitination sites | Identify DUB substrates and pathways |
| Activity-based probes | DUB catalytic activity | Confirm enzyme activity and test inhibitors |
| CRISPR knockout screens | Gene requirement for fitness or phenotype | Discover DUBs in cancer or immune signaling |
| Co-immunoprecipitation | Protein-protein interactions | Map DUB complexes and substrates |
| Fluorescent reporters | Signaling pathway activity | Measure NF-kB or ferroptosis in DUB models [3,8] |
| Lipid accumulation assays | Hepatic steatosis | Test RPN11 inhibitors in NAFLD models |
| Histone modification analysis | Histone ubiquitination | Study PSMD14 in myelomagenesis |
| Metabolic flux assays | Nutrient handling | Study OTUD3 in metabolic stress |
Ubiquitin remnant profiling and proteomics
Mass spectrometry-based ubiquitin remnant profiling can quantify changes in ubiquitination sites after DUB perturbation. This approach identifies direct and indirect substrates of GO:0101005 activity and has been used in proteome-scale effector discovery.
Activity-based probes and biochemical assays
Activity-based probes and fluorogenic substrates measure DUB catalytic activity in lysates or purified systems. These assays are essential for confirming that a candidate enzyme indeed has deubiquitinase activity and for testing inhibitors.
CRISPR screens and functional genomics
Pooled CRISPR knockout screens can identify DUBs required for cell fitness, drug resistance or immune signaling. Such screens have revealed DUBs as effectors of protein degradation and stabilization.
Cell-based signaling and disease models
Reporter assays, co-immunoprecipitation and disease-relevant cell models (e.g., cardiomyocytes, hepatocytes, myeloma cells) are used to link DUB activity to phenotypes such as ferroptosis, lipid accumulation or NF-kB activation [1,3,4,8].
How CRISPR Can Be Used to Study GO:0101005 deubiquitinase activity
Knockout
CRISPR knockout of a DUB gene eliminates GO:0101005 activity for that enzyme, enabling loss-of-function studies. For example, knocking out PSMD14 can test its requirement in myeloma cell growth and histone ubiquitination. Knockout of OTUD1 can reveal its role in restraining colonic inflammation.
Point Mutation
Point mutation of the catalytic cysteine or other key residues abolishes DUB activity while preserving protein expression. This is critical to distinguish catalytic activity from scaffolding functions, as emphasized in DUB mechanism studies.
Knock-in
Knock-in of disease-associated variants or tagged alleles allows precise modeling of DUB dysfunction. Tagged knock-in can also be used to track DUB localization and interactions in vivo.
Overexpression
Overexpression of wild-type or mutant DUBs can phenocopy disease states and test gain-of-function mechanisms. For example, overexpression of OTUD3 or OTUD5 can be used to study metabolic stress and ferroptosis protection [3,5].
How EDITGENE Supports deubiquitinase activity Research
Researchers studying deubiquitinase activity-related genes often need to determine whether a candidate gene is causally involved in a disease or pathway. This requires well-controlled genetic models that isolate DUB catalytic activity from other protein functions. EDITGENE provides end-to-end CRISPR services to generate such models efficiently.
Contact EDITGENE today to design your custom CRISPR model for deubiquitinase activity research.
Frequently Asked Questions About deubiquitinase activity
What is deubiquitinase activity?
Deubiquitinase activity (GO:0101005) is an isopeptidase activity that cleaves ubiquitin from a target protein to which it is conjugated, reversing ubiquitination.
What genes are involved in deubiquitinase activity?
Genes encoding DUBs include PSMD14, OTUD5, OTUD3, OTUD1, USP7, USP28, BAP1, CYLD and many others [1,3,4,5,6,8].
What is the GO ID for deubiquitinase activity?
The Gene Ontology ID is GO:0101005, with synonym ubiquitinyl hydrolase activity.
How does deubiquitinase activity differ from ubiquitination?
Ubiquitination attaches ubiquitin to proteins, while deubiquitinase activity removes it, making the modification reversible.
Which diseases are linked to deubiquitinase activity?
DUBs are linked to cancer, nonalcoholic fatty liver disease, myocardial ischemia/reperfusion injury and colonic inflammation [1,3,4,8].
How can I study deubiquitinase activity in the lab?
Common methods include activity-based probes, ubiquitin remnant profiling, CRISPR knockout and cell-based signaling assays [2,7].
What is the role of PSMD14 in cancer?
PSMD14/RPN11 has histone deubiquitinase activity and drives myelomagenesis, making it a target in multiple myeloma.
Can deubiquitinase activity be inhibited therapeutically?
Yes, inhibiting RPN11 ameliorates nonalcoholic fatty liver disease in preclinical models.
What CRISPR models are used for DUB research?
Knockout, point-mutation, knock-in and overexpression models are all used to dissect DUB function [2,7].
Why is deubiquitinase specificity important?
DUB specificity ensures that only particular substrates or ubiquitin linkages are cleaved, preventing unwanted protein stabilization.
Conclusion
Deubiquitinase activity (GO:0101005) is a fundamental molecular function that reverses ubiquitination and controls protein fate, signaling and metabolism. Its roles in cancer, metabolic disease, ferroptosis and inflammation make it a high-priority target for mechanistic and translational research [1,3,4,5,6,8]. Advances in CRISPR modeling and proteomics now allow precise interrogation of DUB function and substrate specificity [2,7]. Researchers can leverage these tools to uncover new biology and therapeutic opportunities centered on GO:0101005.
References
- 1. He L et al.. 2023. The proteasome component PSMD14 drives myelomagenesis through a histone deubiquitinase activity.. Mol Cell 83(22):4000-4016.e6 PMID: 37935198
- 2. Mevissen TET et al.. 2017. Mechanisms of Deubiquitinase Specificity and Regulation.. Annu Rev Biochem 86:159-192 PMID: 28498721
- 3. Liu L et al.. 2023. Deubiquitinase OTUD5 as a Novel Protector against 4-HNE-Triggered Ferroptosis in Myocardial Ischemia/Reperfusion Injury.. Adv Sci (Weinh) 10(28):e2301852 PMID: 37552043
- 4. Zhou B et al.. 2024. Amelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11.. Cell Metab 36(10):2228-2244.e7 PMID: 39146936
- 5. Zhou N et al.. 2022. Deubiquitinase OTUD3 regulates metabolism homeostasis in response to nutritional stresses.. Cell Metab 34(7):1023-1041.e8 PMID: 35675826
- 6. Dewson G et al.. 2023. Deubiquitinases in cancer.. Nat Rev Cancer 23(12):842-862 PMID: 37935888
- 7. Poirson J et al.. 2024. Proteome-scale discovery of protein degradation and stabilization effectors.. Nature 628(8009):878-886 PMID: 38509365
- 8. Wu B et al.. 2022. The deubiquitinase OTUD1 inhibits colonic inflammation by suppressing RIPK1-mediated NF-κB signaling.. Cell Mol Immunol 19(2):276-289 PMID: 34876703
